The price of Sagimet Biosciences Inc (NASDAQ:SGMT) shares last traded on Wall Street fell -3.95% to $8.27.
SGMT stock price is now 136.13% away from the 50-day moving average and 99.16% away from the 200-day moving average. The market capitalization of the company currently stands at $253.68M.
With the price target of $30, Oppenheimer recently initiated with Outperform rating for Sagimet Biosciences Inc (NASDAQ: SGMT). On November 12, 2024, UBS recently initiated its ‘Buy’ rating on the stock quoting a target price of $12, while ‘Goldman’ rates the stock as ‘Neutral’
In other news, Kemble George, Executive Chairman sold 23,625 shares of the company’s stock on Jul 23 ’24. The stock was sold for $74,830 at an average price of $3.17. Upon completion of the transaction, the Executive Chairman now directly owns 118,693 shares in the company, valued at $0.98 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jul 19 ’24, Chief Medical Officer Martins Eduardo Bruno sold 8,357 shares of the business’s stock. A total of $25,910 was realized by selling the stock at an average price of $3.10. This leaves the insider owning 81,213 shares of the company worth $0.67 million. A total of 26.63% of the company’s stock is owned by insiders.
During the past 12 months, Sagimet Biosciences Inc has had a low of $1.73 and a high of $8.78. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 20.26, and a quick ratio of 20.26. The fifty day moving average price for SGMT is $3.5023 and a two-hundred day moving average price translates $4.152375 for the stock.
The latest earnings results from Sagimet Biosciences Inc (NASDAQ: SGMT) was released for 2025-03-31.
